• info@microlabs.in
  • +91-80-2237 0451-57 / +91-80-2237 0463
  • ADR
  • Blogs
  • Contact
Logo
  • About
    • About Micro Labs
    • Vision & Values
    • Awards & Milestones
  • Business Segment
    • API
    • Formulations
    • Therapies
  • Infrastructure
    • Manufacturing Plants
    • R&D
  • Global Presence
  • Social Impact
  • Media
    • News & Press
    • announcements

News & Press

  • Home
  • News & Press
Thumb

How Dolo 650 became the Go to Drug during the pandemic

  • The India Express

Easy availability and being the doctors’ preferred prescription during the second wave.

Thumb

How Micro Labs struck Gold with Dolo-650

  • Forbes India

The company has sold 350 crore tablets since the Covid-19 outbreak in 2020, and earned revenues of Rs 400 crore in a year

Thumb

The Brand Story Media recognized Dolo-650 as India’s leading brand

  • Hindustan Times

Dolo-650 gets recognized as India’s Leading Brand at the Indian Brand and Leadership Conclave 2022 organized by The Brand Story.

Thumb

Micro Labs Ltd, disrupting the Indian pharmaceutical industry since 1973

  • The CEO Magazine

Today, Dolo-650 is the 6th largest brand (as per AWACS) in the Indian Pharmaceutical Market became the number one prescribed brand of paracetamol solid oral doses in India.

Thumb

Introducing Trisopt: The World's First Triple Drug Combo for Glaucoma

  • The Print

Micro Labs Ltd introduces Trisopt: World’s first triple drug fixed-dose combination for Glaucoma Management.Trisopt is an indigenous development from Micro Labs, manufactured in their state-of-the-art facility located in Sikkim.

Quick Links

  • Home
  • Blogs
  • Contact Us

About

  • About Micro Labs
  • Global Presence
  • Vision & Values
  • Awards & Milestones

Infrastructure

  • Manufacturing Plants
  • R&D

Business

  • API
  • Formulations
  • Therapies
  • Social Impact

Media

  • Blogs
  • News & Press
  • Announcements

Policies

  • Privacy Policy
  • NRC
  • Code of Conduct
  • Vigil Mechanism
  • CSR

Copyright©️MICRO LABS LTD. All rights reserved.

  • Developed By @BubbleNetwork